Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SoC Therapy Clear all
Completed Phase 4 Interventional Results available

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

NCT03927144
View directory record Official record
Conditions
Episodic Migraine
Interventions
AMG334, Oral Prophylactic
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Stanford, California • New Haven, Connecticut • Stamford, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 29, 2026, 5:15 AM EDT
Withdrawn Not applicable Interventional

Influence of Pharmacist and Student Pharmacists on Medication Adherence in Community Pharmacy Setting in Underserved Population

NCT04376112
View directory record Official record
Conditions
Diabetes, Medication Non Adherence, Blood Pressure, Pharmacist-Patient Relations
Interventions
Pharmacist and pillpack intervention, Standard of care
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Chandler, Arizona • Tucson, Arizona • Fullerton, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

NCT04186247
View directory record Official record
Conditions
Crohn Disease, Pediatric Crohns Disease
Interventions
Azithromycin, Metronidazole, Standard of Care
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

NCT06150417
View directory record Official record
Conditions
Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
Interventions
Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT), Metastasis directed radiotherapy (MDRT)
Drug · Other · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)

NCT02483429
View directory record Official record
Conditions
Vertigo, Dizziness
Interventions
VRT Care
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Peoria, Illinois • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 29, 2026, 5:15 AM EDT
Not yet recruiting Not applicable Interventional

PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers

NCT07779239
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs)
Interventions
Bonvadis® (NWBOT), Clostridial Collagenase Ointment
Device
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
North Port, Florida • Palm Coast, Florida • South Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT07340541
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing

NCT05424354
View directory record Official record
Conditions
Wounds and Injuries
Interventions
Altrazeal (R) Transforming Powder Dressing, Standard of Care burn dressing
Device · Other
Lead sponsor
ULURU Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Orange, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

NCT01052103
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Placebo, Standard of Care
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer

NCT01670461
View directory record Official record
Conditions
Cancer
Interventions
FACE, Standard of Care (SOC) Control
Behavioral
Lead sponsor
Maureen Lyon
Other
Eligibility
14 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)

NCT02922153
View directory record Official record
Conditions
Pain
Interventions
Cryoanalgesia, Standard of Care
Device · Drug
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Ann Arbor, Michigan • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
54
States / cities
Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

NCT00503880
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
filgrastim, clofarabine, cytarabine, microarray analysis, biopsy
Biological · Drug · Genetic + 1 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

NCT03700320
View directory record Official record
Conditions
Episodic Migraine
Interventions
Standard of Care (SOC) Migraine Preventive Medication, Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
112
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 29, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

NCT05900050
View directory record Official record
Conditions
Acute-On-Chronic Liver Failure, Ascites
Interventions
VS-01 on top of SOC, SOC (Control Group)
Drug · Other
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer

NCT02784288
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Cancer
Interventions
Neck Dissection, Standard-of-Care (SOC) Transoral Surgery of Primary Site, SOC Radiation, SOC Carboplatin, SOC Paclitaxel, Videofluoroscopy
Procedure · Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 29, 2026, 5:15 AM EDT
Completed No phase listed Observational

Scratch Behavior Under Standard of Care

NCT03898427
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Wrist Actigraphy Devices, Polysomnography, Videography
Device
Lead sponsor
Boston University
Other
Eligibility
2 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

NCT02949362
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide, SOC
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 29, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310
View directory record Official record
Conditions
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Withdrawn Not applicable Interventional

Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

NCT05130346
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
Interventions
Mindfulness Based Stress Reduction (MBSR)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 29, 2026, 5:15 AM EDT